Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 20, 2021
Atea Announces Update and Topline Results of MOONSONG Study Evaluating AT-527 for COVID-19 in the Outpatient Setting
TOKYO, October 20, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Atea issued a press release on October 19 regarding update and topline results of MOONSONG study evaluating the RNA polymerase inhibitor AT-527 for COVID-19 in the outpatient setting.
Please refer to the link below for details of the press release:
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-and-topline-results-phase-2
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
